10月10日，利德曼盘中上涨2.01%，截至10:38，报7.61元/股，成交4721.55万元，换手率1.15%，总市值 41.40亿元。 资金流向方面，主力资金净流入293.52万元，特大单买入142.01万元，占比3.01%，卖出0.00元，占比 0.00%；大单买入848.17万元，占比17.96%，卖出696.67万元，占比14.76%。 利德曼今年以来股价涨55.31%，近5个交易日跌0.13%，近20日跌3.79%，近60日涨41.19%。 利德曼所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基因测序、辅助生殖、体 外诊断、冷链物流、小盘等。 截至9月19日，利德曼股东户数3.35万，较上期减少4.99%；人均流通股16192股，较上期增加5.26%。 2025年1月-6月，利德曼实现营业收入1.60亿元，同比减少14.80%；归母净利润-424.52万元，同比减少 800.43%。 分红方面，利德曼A股上市后累计派现1.43亿元。近三年，累计派现544.01万元。 机构持仓方面，截止2025年6月30日，利德曼十大流通股东中，金元顺安元启灵活配置混合（004685） 位居第八 ...

10月9日，华大智造盘中上涨2.02%，截至13:34，报70.57元/股，成交1.61亿元，换手率0.56%，总市值 293.94亿元。 资金流向方面，主力资金净流入213.58万元，特大单买入980.85万元，占比6.10%，卖出388.10万元，占 比2.41%；大单买入3111.68万元，占比19.36%，卖出3490.85万元，占比21.72%。 资料显示，深圳华大智造科技股份有限公司位于广东省深圳市盐田区北山工业区综合楼及11栋2楼，成 立日期2016年4月13日，上市日期2022年9月9日，公司主营业务涉及专注于生命科学与生物技术领域,以 仪器设备、试剂耗材等相关产品的研发、生产和销售。 华大智造所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：基因测序、合成生物、 医疗器械、精准医疗、中盘等。 责任编辑：小浪快报 截至6月30日，华大智造股东户数1.35万，较上期增加7.64%；人均流通股15766股，较上期减少7.09%。 2025年1月-6月，华大智造实现营业收入11.14亿元，同比减少7.90%；归母净利润-1.04亿元，同比增长 65.28%。 分红方面，华大智造A股上市 ...

资金流向方面，主力资金净流入1516.41万元，特大单买入1892.06万元，占比16.07%，卖出119.71万 元，占比1.02%；大单买入2560.02万元，占比21.75%，卖出2815.97万元，占比23.92%。 马应龙今年以来股价涨5.85%，近5个交易日涨0.37%，近20日涨1.24%，近60日涨0.33%。 资料显示，马应龙药业集团股份有限公司位于湖北省武汉市武昌南湖周家湾100号，成立日期1994年5月 9日，上市日期2004年5月17日，公司主营业务涉及药品制造、医药零售及批发以及医疗服务等。主营业 务收入构成为：治痔类45.53%，零售、批发34.93%，其他16.43%，医院诊疗3.11%。 马应龙所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：基因测序、医药电商、中药、 化妆品、民营医院等。 10月9日，马应龙盘中上涨2.00%，截至11:20，报26.98元/股，成交1.18亿元，换手率1.02%，总市值 116.30亿元。 截至6月30日，马应龙股东户数3.11万，较上期减少23.07%；人均流通股13825股，较上期增加29.98%。 2025年1月-6月，马应 ...

10月9日，艾德生物盘中下跌2.04%，截至10:01，报22.53元/股，成交5690.06万元，换手率0.64%，总市 值88.21亿元。 截至6月30日，艾德生物股东户数2.53万，较上期增加5.41%；人均流通股15393股，较上期减少5.13%。 2025年1月-6月，艾德生物实现营业收入5.79亿元，同比增长6.69%；归母净利润1.89亿元，同比增长 31.41%。 分红方面，艾德生物A股上市后累计派现4.21亿元。近三年，累计派现2.32亿元。 机构持仓方面，截止2025年6月30日，艾德生物十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股3167.06万股，相比上期减少351.59万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股903.66万股，为新进股东。华安聚优精选混合（009714）、汇添富价值精选混合（519069）、 工银创新动力股票（000893）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出844.62万元，特大单买入0.00元，占比0.00%，卖出108.79万元，占比 1.91%；大单买入867.59万元，占比15. ...

10月9日，新开源盘中上涨2.10%，截至09:47，报18.02元/股，成交4022.71万元，换手率0.50%，总市值 87.59亿元。 分红方面，新开源A股上市后累计派现9.00亿元。近三年，累计派现6.07亿元。 资金流向方面，主力资金净流入121.61万元，特大单买入105.43万元，占比2.62%，卖出100.26万元，占 比2.49%；大单买入902.90万元，占比22.45%，卖出786.46万元，占比19.55%。 责任编辑：小浪快报 新开源所属申万行业为：基础化工-化学制品-其他化学制品。所属概念板块包括：创新药、基因测序、 生物医药、干细胞、精准医疗等。 截至9月10日，新开源股东户数2.05万，较上期减少6.39%；人均流通股21942股，较上期增加6.83%。 2025年1月-6月，新开源实现营业收入6.44亿元，同比减少12.36%；归母净利润1.39亿元，同比减少 34.74%。 新开源今年以来股价涨14.77%，近5个交易日跌4.10%，近20日跌3.53%，近60日涨9.80%。 资料显示，博爱新开源医疗科技集团股份有限公司位于河南省焦作市博爱县文化路(东段)1888号，成立 ...

在中国的NIPT市场，按样本检测量计算，安诺优达在2024年排名第二，市场份额为15.5%；按收入计 算，排名第三，市场份额为14.6%。公司的科研测序解决方案服务于农业、林业、畜牧业及渔业等领域 的多组学研究。 截至2025年9月23日，公司在中国拥有三家生产厂房，主要生产检测试剂盒及测序仪。 公司主营业务包括分子诊断为基础的IVD医疗器械和多组学生命科学研究服务，尤其擅长基于NGS的产 前检测IVD产品。其临床测序解决方案涵盖IVD检测试剂盒、基因测序仪及生物信息学分析软件，并提 供技术支持和实验室设计服务。 安诺优达向港交所主板递交上市申请，联席保荐人为建银国际和国泰君安国际。 ...

Company Overview - He Eye Hospital Group, established on October 15, 2009, is located in Shenyang, Liaoning Province, and was listed on March 22, 2022 [1] - The company primarily provides specialized ophthalmic diagnosis and treatment services, with revenue composition as follows: Vision services 30.24%, Refractive surgery correction services 24.16%, Non-surgical treatment 20.02%, Cataract diagnosis and treatment services 13.68%, Vitreoretinal diagnosis and treatment services 8.09%, Other ophthalmic diagnosis and treatment services 3.20%, Other business income 0.61% [1] Financial Performance - As of June 30, 2025, He Eye Hospital reported operating revenue of 560 million yuan, a year-on-year decrease of 4.22%, while net profit attributable to shareholders was 44.32 million yuan, reflecting a year-on-year increase of 84.19% [2] - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] Stock Performance - As of September 30, the stock price of He Eye Hospital increased by 2.14% to 21.03 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Year-to-date, the stock price has risen by 5.29%, with a 1.69% increase over the last five trading days, but a decline of 3.93% over the last 20 days and 3.53% over the last 60 days [1] - The number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3]

Company Overview - Dongfulong Technology Group Co., Ltd. is located in Minhang District, Shanghai, established on December 25, 1993, and listed on February 1, 2011 [2] - The company specializes in the research, design, production, sales, and service of medical freeze-dryers and freeze-drying systems [2] Financial Performance - For the first half of 2025, Dongfulong achieved operating revenue of 2.429 billion yuan, a year-on-year increase of 6.01%, while net profit attributable to shareholders decreased by 59.71% to 45.9195 million yuan [2] - The company has cumulatively distributed 1.782 billion yuan in dividends since its A-share listing, with 512 million yuan distributed over the past three years [3] Stock Performance - As of September 29, Dongfulong's stock price decreased by 2.02% to 14.10 yuan per share, with a total market capitalization of 10.798 billion yuan [1] - Year-to-date, the stock price has increased by 7.02%, with a slight increase of 0.14% over the last five trading days, a decrease of 2.96% over the last 20 days, and an increase of 8.05% over the last 60 days [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 2.35% to 32,100, with an average of 17,526 circulating shares per person, a decrease of 2.30% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 7.3336 million shares, a decrease of 2.1354 million shares from the previous period, while Southern CSI 1000 ETF is a new shareholder with 3.5502 million shares [3] Capital Flow - On September 29, the net outflow of main funds was 8.5515 million yuan, with no large orders bought and 2.5647 million yuan sold, accounting for 3.76% [1]

9月26日，诺唯赞盘中上涨2.03%，截至13:48，报23.13元/股，成交3811.18万元，换手率0.42%，总市值 92.00亿元。 资料显示，南京诺唯赞生物科技股份有限公司位于江苏省南京经济技术开发区科创路红枫科技园D2 栋，成立日期2012年3月16日，上市日期2021年11月15日，公司主营业务涉及围绕酶、抗原、抗体等功 能性蛋白及高分子有机材料进行技术研发和产品开发的生物科技企业,依托于自主建立的关键共性技术 平台,先后进入了生物试剂、体外诊断业务领域,并正在进行抗体药物的研发。主营业务收入构成为：生 物试剂81.86%，诊断试剂9.99%，耗材等材料3.15%，仪器设备2.96%，技术服务1.85%，其他0.18%。 诺唯赞所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：基因测序、抗原检 测、体外诊断、合成生物、小盘等。 截至6月30日，诺唯赞股东户数8596.00，较上期增加2.37%；人均流通股46269股，较上期减少2.31%。 2025年1月-6月，诺唯赞实现营业收入6.06亿元，同比减少6.63%；归母净利润312.94万元，同比减少 80.63%。 资金流向方 ...

Company Overview - Dongfulong Technology Group Co., Ltd. is located in Minhang District, Shanghai, established on December 25, 1993, and listed on February 1, 2011. The company specializes in the research, design, production, sales, and service of medical freeze-dryers and freeze-drying systems [1]. Financial Performance - As of June 30, 2025, Dongfulong achieved operating revenue of 2.429 billion yuan, representing a year-on-year growth of 6.01%. However, the net profit attributable to shareholders decreased by 59.71% to 45.9195 million yuan [2]. - The company has cumulatively distributed dividends of 1.782 billion yuan since its A-share listing, with 512 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Dongfulong's stock price increased by 2.19%, reaching 14.46 yuan per share, with a total market capitalization of 11.074 billion yuan. The stock has seen a year-to-date increase of 9.75% [1]. - The stock's trading volume on September 25 was 70.291 million yuan, with a turnover rate of 0.88%. The net outflow of main funds was 1.516 million yuan, while large orders saw a buy of 9.4811 million yuan and a sell of 12.2223 million yuan [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 32,100, with an average of 17,526 circulating shares per person, a decrease of 2.30% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.3336 million shares, a decrease of 2.1354 million shares from the previous period, while Southern CSI 1000 ETF entered as a new shareholder with 3.5502 million shares [3]. Business Segments - Dongfulong's main business revenue composition includes: 44.92% from the formulation division, 29.83% from the bioprocess division, 9.19% from the engineering division, 9.16% from the food division, 6.81% from after-sales service and parts, and 0.09% from other sources [1].